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Abstract:  
Myocardial damage as a consequence of cardiotropic viruses leads to a broad variety of clinical 
presentations and is still a complicated condition to diagnose and treat. Whereas the 
extracellular matrix protein Secreted Protein Acidic and Rich in Cysteine or SPARC has been 
implicated in hypertensive and ischemic heart disease by modulating collagen production and 
cross-linking, its role in cardiac inflammation and endothelial function is yet unknown.  
Absence of SPARC in mice resulted in increased cardiac inflammation and mortality, and 
reduced cardiac systolic function upon coxsackievirus-B3 induced myocarditis. Intra-vital 
microscopic imaging of the microvasculature of the cremaster muscle combined with electron 
microscopic imaging of the microvasculature of the cardiac muscle uncovered the significance 
of SPARC in maintaining endothelial glycocalyx integrity and subsequent barrier properties to 
stop inflammation. Moreover, systemic administration of recombinant SPARC restored the 
endothelial glycocalyx and consequently reversed the increase in inflammation and mortality 
observed in SPARC KO mice in response to viral exposure. Reducing the glycocalyx in vivo by 
systemic administration of hyaluronidase, an enzyme that degrades the endothelial glycocalyx, 
mimicked the barrier defects found in SPARC KO mice, which could be restored by subsequent 
administration of recombinant SPARC.  
In conclusion, the secreted glycoprotein SPARC protects against adverse cardiac inflammation 
and mortality by improving the glycocalyx function and resulting endothelial barrier function 
during viral myocarditis. 
 
Keywords: SPARC, endothelial glycocalyx, Viral Myocarditis, extracellular matrix, 
Inflammation 
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Introduction: 
Myocarditis is defined as inflammation of the heart muscle and can be caused by a variety of 
infectious and non-infectious illnesses. Amongst the infectious causes, viruses are supposedly 
the most frequent pathogens affecting the myocardium. The broad variety of clinical 
presentations, make viral myocarditis a complicated condition to diagnose and treat. Despite 
combining the standardized criteria for histological diagnosis of myocarditis [1] with 
endomyocardial biopsy [2], the true incidence is still not precisely known yet, estimating 1 to 10 
cases per 100,000 persons each year.  
Not only can acute viral myocarditis lead to sudden cardiac arrest [5], but it is also a major cause 
of congestive heart failure [6] and in some cases even requires cardiac transplantation. 
Responsible cardiotropic viruses, such as the entero-coxsackie B viruses, can induce this severe 
cardiac inflammation in susceptible patients, resulting in heart failure and possibly sudden 
death. This form of heart disease is particularly devastating as it affects previously healthy 
young adults. In spite of our better understanding of the causative cardiotropic viruses and 
consecutive immunological mechanisms that contribute to the development of cardiac 
dysfunction [7], diagnosis and treatment for myocarditis are still poor. Elucidating the 
underlying mechanisms of enhanced or sustained cardiac inflammation can facilitate the 
development of new specific therapies for viral myocarditis.  
The cardiac extracellular matrix (ECM), comprised of proteoglycans, glycoproteins and 
glycosaminoglycans [8], plays an important role in intercellular communication during cardiac 
disease [9][10]. Since inflammation and heart failure reciprocally trigger one another [11], we 
speculated that ECM proteins may trigger heart failure development by potentiating the 
immune response [12, 13]. When addressing the interaction of the immune system and the 
ECM in cardiac disease however, the prominent vascular gatekeeper known as the endothelial 
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glycocalyx is often overlooked. This while the endothelial glycocalyx is comprised of similar 
proteoglycans, glycoproteins and glycosaminoglycans to the cardiac ECM and is known to 
regulate inflammation, vascular permeability, coagulation and mechanotransduction [14, 15]. 
The endothelial glycocalyx does not just infer the luminal lining of the endothelium but in fact 
encapsulates endothelial cells and expand towards the endothelial basement membrane [14]. 
Therefore, we investigated the role of the endothelial glycocalyx in regulating inflammation in 
viral myocarditis in this study with a specific focus on ECM protein Secreted Protein Acidic and 
Rich in Cysteine (SPARC).  
SPARC has been shown to regulate fibroblast function in connective tissue [16-19] as well as 
tumour development and progression [20, 21], bone homeostasis and repair [22], angiogenesis 
[23] and cardiac ageing [18, 24, 25]. Moreover, both in vitro studies and in vivo murine oncology 
studies have recognised the increased vascular permeability in the absence of SPARC [26, 27], 
however the mechanisms by which SPARC may influence vascular permeability are still unclear. 
Where SPARC has been recognized for its fundamental roles as an adhesive component of the 
ECM, no attention has been given to the extracellular lining of the endothelium as a possible 
immune-regulating structure housing SPARC [14]. As the expression of SPARC is low during 
normal post-natal life but dramatically upregulated upon tissue injury, we contemplated that 
SPARC may influence cardiac inflammation in viral myocarditis and could therefore potentially 
be used as a therapeutic strategy limiting heart failure development. 
The present study reveals that SPARC regulates inflammation, vascular permeability, and 
consequently mortality in a murine coxsackievirus B3 (CVB3) induced myocarditis model by 
regulating the integrity of the endothelial glycocalyx. Above all, this study emphasizes the vital 
role of the endothelial glycocalyx as part of the extracellular matrix in cardiac (patho-
)physiology. 
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Results: 
Absence of SPARC increased cardiac inflammation and mortality in viral myocarditis and 
accelerated the onset of dilated cardiomyopathy. 
As a first step in investigating the role of SPARC during cardiac inflammation, we subjected 
SPARC KO and WT mice to CVB3-induced viral myocarditis. Virus-mediated cardiomyocyte 
damage will induce the infiltration of innate leukocytes (macrophages/monocytes and 
granulocytes), which is followed by adaptive leukocytes (B- and T-lymphocytes). We found that 
significantly more innate and adaptive leukocytes (CD45 positive) infiltrated the heart of 
SPARC KO mice as compared to WT mice at day 7 (0.7±0.2% vs 6.8±1.8% positive staining of 
total left ventricular area for WT and KO respectively; p<0.005 (Figure 1A-B). Furthermore, 
absence of SPARC led to increased mortality (9/21, 43% in KO vs. 11/14, 72% in WT at 7 days; 
p=0.06) (Figure 1C). The viral exposure did not differ as cardiac viral presence was similar in 
SPARC KO as compared to WT mice during peak viremia (day 2) (Figure 1C). While CVB3 injures 
cardiomyocytes, tissue destruction can be potentiated by the recognition of this virus by 
pattern recognition receptors of the innate and adaptive immune system, resulting in the 
production of inflammatory cytokines. Therefore, we measured the expression of viral pattern 
recognition receptors Toll-Like-Receptor 3 (TLR3), melanoma differentiation association 
protein-5 (MDA-5) and retinoic acid inducible gene-1 (RIG-1) and found no difference between 
both groups (Supplemental Figure 1A-C).  
Next, we investigated whether absence of SPARC would affect the recruitment of innate and/ 
or adaptive leukocytes to the injured myocardium. The number of leukocytes either in the 
circulation or in cardiac tissue under normal conditions did not significantly differ between 
SPARC WT and KO mice before CVB3 infection as revealed by flow cytometry (Figure 1E). 
However, as a consequence of viral infection, a rapid recruitment of innate immune cells into 
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the hearts of SPARC KO mice was observed (83440+35,807 CD45+ cells), significantly higher as 
compared to that of non-infected KO mice (14897+4600 CD45+ cells) and infected WT mice 
(30995+5542 CD45+ cells, Figure 1F). Analysis was done at 4 days post CVB3 infection as there 
is onset of inflammation but no mortality is yet observed in particular in the KO animals. Of 
note, the absolute number of Ly6Chigh monocytes was significantly higher in the hearts of 
infected KO mice than WT mice (46014+22943 cells versus 11072+2651 cells), which was also 
true for the granulocyte cells (4601+2192 and 716+186 cells for KO and WT respectively, 
*p<0.05, Figure 1F).  
 
Aggravated leukocyte recruitment in the absence of SPARC was due to changes in vascular 
permeability.  
As we found that lack of SPARC clearly resulted in excessive immune infiltration due to viral 
exposure, we wondered whether this would be the consequence of SPARC either influencing 
the vasculature or the leukocytes. SPARC not only co-stained with the endothelium specific 
proteins CD31 and VCAM-1 in CVB3-infected hearts, it also co-localized with Wheat Germ 
Agglutinin (WGA), which is a lectin that recognizes sialic acid and N-acetylglucosamine that are 
present on glycoproteins within the extracellular environment (Figure 2A). SPARC did not co-
localize with CD45+ leukocytes indicating that the influence of SPARC on immune cell 
recruitment during viral myocarditis occurs on the level of the microvasculature (Figure 2A). 
The endothelial glycocalyx is largely composed of carbohydrates found on proteoglycans and 
glycoproteins and regulates vascular permeability. Hence, the endothelial glycocalyx plays a 
central role in modulating the influx of inflammatory cells under homeostasis as well as 
pathophysiological conditions [28-30]. To test whether SPARC absence would induce 
alterations in vascular permeability, two independent analyses were performed. A qualitative 
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analysis of systemically-injected microspheres shows higher amounts of beads in the cardiac 
environment of KO as compared to WT mice (Figure 2B). Likewise, a quantitative analysis of 
Evans blue uptake revealed that KO mice have a more permissive vasculature in the heart as 
compared to WT mice (Figure 2C). During CVB3 infection this was even more pronounced in the 
heart, and also true for the lungs and liver (Figure 2C). Finally, SPARC was detected in a pull 
down of cardiac endothelial cells using heparin-sepharose beads (Figure 2D), suggesting an 
interaction between SPARC and heparan sulphates, one of the major glycocalyx components 
[37, 38].  
 
SPARC absence lead to altered vascular permeability and leukocyte-endothelium 
interactions by impeding glycocalyx integrity. 
As the endothelial glycocalyx regulates leukocyte recruitment [31], the influence of SPARC on 
leukocyte recruitment by modulating the structure lining the endothelium was assessed by 
intra-vital microscopy in the cremaster muscle (Figure 3A). This allows the visualization of the 
microvessels and can be used for the assessment of capillary permeability as well as leukocyte 
adherence, rolling and velocity [32]. The cremaster muscle was consequently stimulated with 
TNF-, a pro-inflammatory cytokine central in the pathogenesis of viral myocarditis, which 
activates the endothelium initiating degradation of the endothelial glycocalyx, enhancing 
leukocyte adhesion and vascular permeability [33], mimicking disease. Capillary leakiness as a 
consequence of TNF- stimulation was significantly higher in SPARC KO as compared to WT 
mice, as quantified by the extravasation of fluorescently labelled dextran (p<0.0001, Figure 3B-
C).  
The malfunctioning endothelial barrier in SPARC KO animals was potentially due to a damaged 
endothelial glycocalyx, as observed with electron microscopy using a specific protocol to 
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preserve the glycocalyx. SPARC KO mice had a severely thinned or nearly absent glycocalyx in 
the capillaries and arterioles in the heart, compared to the normal glycocalyx in WT littermates 
(Figure 3D). We next wondered whether the decreased immune cell recruitment to the 
myocardium of SPARC KO mice was endothelial mediated or leukocyte mediated. As no 
conditional SPARC KO mouse exists, in vitro leukocyte adhesion assay under static conditions 
and under conditions of flow were performed. Freshly isolated leukocytes from KO and WT 
mice adhered equally well to TNF--stimulated WT cardiac microvascular endothelial cells 
under both static and flow conditions (Figure 3E, F). Given the comparable endothelial 
glycocalyx in these cultured primary endothelial cells [34], this experiment suggested that not 
leukocyte derived SPARC but endothelial glycocalyx derived SPARC was responsible for the 
effect on cardiac inflammation. As the endothelial glycocalyx is not only known to influence 
vascular permeability but also plays a significant role in regulating endothelium-leukocyte 
interactions [35], we went back to the in vivo cremaster model to investigate leukocyte 
adhesion and velocity (Figure 3F). In vivo, lack of SPARC resulted in a significant increase of the 
adhesion efficacy - seen as the percentage of adhering cells over total rolling cells [36] – with an 
8.6-fold increase in SPARC KO mice versus a 4-fold increase in SPARC WT mice after TNF-α 
stimulation (p<0.05, Figure 3G, H). In agreement, leukocyte velocities were also significantly 
reduced in SPARC KO mice as compared to WT, both at baseline (*p<0.001, Figure 3I) and 
further reduced after TNF-α stimulation (#/##/**p<0.001, Figure 3I).  
 
Administration of recombinant SPARC restored the function of damaged glycocalyx. 
To show that SPARC’s effect on the glycocalyx was responsible for the observed increased 
inflammatory response, we tested whether glycocalyx damage alone could phenocopy the 
SPARC KO mice. Treatment of WT mice with hyaluronidase (HAase) without consecutive CVB3 
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injection resulted in a severely damaged endothelial glycocalyx as revealed via electron 
microscopy revealed, that could be partially restored by a single injection of recombinant 
SPARC (Figure 4A). To see whether HAase impeded glycocalyx-associated endothelial barrier 
properties, and whether these could be restored by recombinant SPARC administration, we 
again went back to the cremaster model. Degradation of the glycocalyx by injection of HAase 
resulted in the expected increase in vascular leakiness (p>0.0005, Figure 4B-C) and reduction of 
leukocyte velocities (p<0.001, Figure 4D). Above all, leukocyte velocities and microvascular 
leakiness were restored back to baseline values in response to recombinant SPARC 
administration that followed enzymatic degradation of the endothelial surface layer (Figure 4B-
D). Finally, we wondered whether lack of glycocalyx by HAase treatment prior to CVB3 
infection could phenocopy SPARC KO mice. As anticipated, HAase treatment significantly 
increased the cardiac infiltration 7 days after viral infection (4±1% in nontreated -HAase vs. 
9±2% in treated +HAase; p0.05, Figure 4E-F) without affecting mortality. Similarly to when 
SPARC is absent, HAase treatment did not affect the viral levels during the viremic phase 
(Figure 4G).  
 
Administration of recombinant SPARC reduced cardiac inflammation and mortality in 
SPARC KO mice. 
In order to explore the long-term effect of SPARC loss on cardiac function after viral 
myocarditis, SPARC KO and WT mice underwent echocardiographic assessments at 4 days and 
9 weeks after viral infection. Concomitantly a group of KO and WT mice received SPARC 
systemically for 5 weeks and also underwent echocardiographic evaluation (Table 1). 
Interestingly, dilated cardiomyopathy started to present only in the KO mice at 9 weeks post 
viral exposure (p=0.02 and p=0.04, for fractional shortening FS and left ventricular systolic 
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dimension respectively, Table 1). This functional deterioration observed in SPARC null mice 
could unfortunately not be prevented by systemic SPARC administration. However, SPARC 
administration did significantly improve the survival of KO mice (14/15, p=0.009, Figure 5B-C) 
without having any benefit on survival in their WT littermates. The improved survival as a result 
of recombinant SPARC administration in SPARC null mice, was reflected by the decrease in 
cardiac inflammation (p<0.05, Figure 5D-E). In trying to identify a possible mortality cause for 
these mice we hypothesised that aggravated cardiac inflammation might lead to 
electrophysiological disturbances. Electrocardiographic measurements were performed on 
SPARC WT mice, SPARC KO mice either treated or non-treated with recombinant SPARC. 
Unexpectedly, while there were no significant differences in heart rates between all animals, 
QTc times were reduced in SPARC KO mice compared to WT yet could not be restored upon 
recombinant SPARC administration (**p<0.05, Figure 5F,G).  
 
Discussion: 
Viral myocarditis is a clinical entity that is still very difficult to diagnose let alone treat. Not only 
does it result in sudden cardiac arrest it can eventually lead to heart failure development. As the 
ECM is a vital player regulating cardiac remodelling, we studied the glycoprotein SPARC and 
showed that its absence enhanced cardiac inflammation and mortality in the CVB3 induced 
murine model of viral myocarditis. Knowing the importance of the endothelium in recruiting 
leukocytes and the clear immunohistochemical localization of SPARC on the endothelium, our 
interest was drawn to the endothelial glycocalyx. Whilst the endothelial glycocalyx is comprised 
of similar building blocks found in the ECM and is known for regulating leukocyte recruitment 
and vascular permeability, we show for the first time that extracellular matrix protein SPARC is 
an essential regulator of microvascular barrier function. Lack of SPARC results in a loss of 
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glycocalyx integrity and consecutive barrier function as leukocyte adhesion and vascular 
permeability increase when the endothelial glycocalyx is compromised, either by lack of SPARC 
or by enzymatic degradation of one of its major components (hyaluronan). These alterations in 
glycocalyx integrity result in increased cardiac inflammation and mortality during viral 
myocarditis. Most importantly, administration of recombinant SPARC was able to reverse the 
adverse effects of the glycocalyx damage, and restore the associated glycocalyx functional 
impairment resulting in reduced vascular leakage.  
 
The composition of the glycocalyx is controlled by multiple factors and requires a timely 
balance between synthesis and degradation. Though little is known about the regulation of the 
glycocalyx, there is growing appreciation of its importance in organ homeostasis and disease. 
Numerous studies show that changes in shear stress, hypoxia, hyperglycemia, oxidized LDL or 
inflammation can induce glycocalyx perturbation and hence contribute to the vascular 
dysfunction observed in sepsis [39], acute respiratory syndrome [40], albuminuria [41], 
atherosclerosis [42], diabetes [43] and obesity [44]. Changes in myocardial glycocalyx have 
been observed in cardiac pathologies such as ischemia-reperfusion injury [45], excessive 
oedema [46] and cardiogenic shock [47]. Furthermore, a review about the cardiovascular 
manifestations of dengue fever, suggested that alterations in glycocalyx might contribute to 
the capillary leakiness observed during infection and contribute to the myocarditis observed 
[48]. However this study is the first to implicate glycocalyx perturbations to the 
pathophysiology of viral myocarditis. 
Whilst the need to have SPARC for proper endothelial glycocalyx composition has not been 
identified before, in vitro studies have shown that SPARC can bind to albumin [49], which itself 
can regulate glycocalyx integrity [41]. The immunomodulatory role of SPARC in previous 
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studies using in vitro experiments, was ascribed to leukocyte-derived SPARC facilitating 
leukocyte transmigration across an endothelial monolayer [50], and to endothelial cytoskeleton 
rearrangements induced by SPARC treatment [51]. However, the role of SPARC on 
inflammation has been bi-directional in current literature as few studies elude to either a pro- or 
anti-inflammatory effect of SPARC. In a murine-model for pulmonary fibrosis SPARC is 
identified as anti-inflammatory [52], whereas it clearly enhances leukocyte recruitment in a 
murine peritonitis model [53]. The mechanism whereby SPARC affects inflammation in these 
models by either influencing TGFβ activity or interacting with VCAM-1 [54], fail to 
comprehensively explain these contradictory findings. Here, the importance of SPARC in 
endothelial glycocalyx composition and function may clarify its bi-directional role on 
inflammation. Indeed, differential presence of SPARC in the endothelial surface layer of 
different vascular beds may explain the seemingly opposing effect SPARC has on inflammation 
in different tissues and disease models. Although it is well established that every vascular bed 
has very unique structural and functional characteristics [55, 56], whether these unique 
endothelial characteristics will lead to specific and distinctive glycocalyx composition has 
unfortunately not been demonstrated yet, mainly due to technical limitations. Nevertheless, 
we do know that the endothelial glycocalyx consist of numerous complex soluble and insoluble 
glycoproteins, proteoglycans and glycosaminoglycan’s mostly produced by the endothelial 
cells. Further, the thickness of this structure can vary enormously [14] throughout the 
vasculature. We therefore strongly believe that glycocalyx composition can differ between 
various vascular beds as a consequence of unique structural and functional characteristics of the 
endothelium; hence differential SPARC presence in the glycocalyx could affect inflammation 
differently in different tissues and in different diseases, also explaining the opposing effect 
found using in vitro models.  
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Glycoproteins have been suggested as important ‘backbone’ molecules for the glycocalyx 
structure [14]. It is possible that the reduced endothelial barrier properties in SPARC KO mice 
are a consequence of a lack of proper glycocalyx anchoring rather than an impaired glycocalyx 
synthesis. Interestingly, there have been studies showing successful restoration of the shedded 
endothelial glycocalyx after administration of heparan sulphate, one of the major components 
of the glycocalyx in vitro [57]. Considering our heparan sulphate pull down showed a clear 
binding of SPARC to this prevalent glycosaminoglycan, and the clear improvement of 
endothelial barrier properties after administration of recombinant SPARC, we considered the 
possible importance of SPARC-heparan sulphate interaction in glycocalyx regeneration as 
proposed by Ebong et al [57]. However, the exact mechanism via which SPARC affects the 
glycocalyx needs to be further elaborated.  
 
During myocarditis, systemic SPARC administration rescued KO mice survival though it did not 
affect the amount of myocyte cell injury as measured by troponin levels at day 7 post viral 
exposure (Supplementary Figure 1D). Furthermore, inflammatory dilated cardiomyopathy 
develops progressively over time in CVB3 induced viral myocarditis in mice and is prevalent as a 
consequence of cardiomyocyte loss and adverse cardiac inflammation[58]. Similarly to the 
clinical scenario, dilated cardiomyopathy was not present in all CVB3 infected mice at 9 weeks. 
However, we did observe dilated cardiomyopathy mainly in KO mice and less in WT mice. 
Moreover, administration of recombinant SPARC improved cardiac function in SPARC KO mice. 
These data are in line with other studies showing that limiting the cardiac infiltration during the 
acute phase improves the long-term function [59]. 
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Where administration of recombinant SPARC clearly improved glycocalyx integrity and 
consecutive inflammation and mortality, the exact cause of death in SPARC KO mice still 
remains elusive. Electrocardiographic analysis did reveal a shortening of the QTc time in SPARC 
KO mice as compared to WT, which has been correlated with increased mortality as a 
consequence of cardiac arrhythmias [60]. Interestingly, it has been suggested that glycosylated 
proteins comprising the endothelial glycocalyx are vital mechanosensors that initiate the 
production of nitric oxide (NO) resulting in coronary artery dilation and suppression of platelet 
aggregation [61-65]. As coronary flow can be reduced in myocarditis mimicking acute coronary 
syndrome [66], lack of proper mechanosensing may therefore contribute to the functional 
deterioration and, combined with increasing inflammation, eventual lead to arrhythmias and 
death in SPARC KO mice. However, the present study concentrated on the effects of SPARC at 
the level of endothelial glycocalyx and can thus not rule out potential additive/negative effects 
of SPARC at the level of the single cardiac myocyte. 
 
Collectively, our data identify SPARC as crucial component of the endothelial barrier and thus 
prevents pathological cardiac inflammation and mortality. SPARC may therefore represent a 
novel therapeutic tool to repair or maintain endothelial barrier integrity in cardiac disease. 
 
Material and Methods: 
Animals 
C57Bl6/J male SPARC-KO (backcrossed 10 times) and WT C57Bl6/J mice (Harlan, the 
Netherlands) between 10–18 weeks of age were used. Mice were maintained in specific 
pathogen-free facilities at Maastricht or Leuven University. The Animal Care and Use 
Committee of the University of Maastricht and Leuven approved all described study protocols, 
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according to the Dutch (2012/031) and Belgian law (067/2008, 043/2013) and all animal 
procedures were performed conform to the guidelines from Directive 2010/63/EU of the 
European Parliament.  
 
 
 
Murine CVB3 induced viral myocarditis model 
Eight to 12-week old inbred C57Bl6/J SPARC-KO and WT mice were inoculated intra-peritoneal 
(i.p.) with 1×107 cell culture 50% infective dose (CCID50) of CVB3 (Nancy Strain) and cardiac 
immune cell infiltration was measured 7 days later. For long-term administration (5 weeks) 
mice received SPARC via osmotic minipump. Troponin was measured using a high sensitivity 
ELISA 7 days after viral exposure (Roche Diagnostics). Mice received hyaluronidase (iv 70U) [67] 
one hour prior to CVB3. All animals were anaesthetized with an intra-peritoneal injection of 
xylazine (10mg/kg) and ketamine (100mg/kg) and sacrificed by cervical dislocation. Male mice 
were used for all experiments except for the long-term 9-weeks viral myocarditis experiment 
where both Female WT and KO mice were included in equal numbers. 
 
Mouse cremaster preparation and intravital microscopy 
Mice were anesthetized and the exposed muscle was positioned on a clear Silicon pedestal and 
longitudinally incised from the apex to the inguinal canal with minimal disruption of the 
vascular supply. The stage of the intravital microscope (Olympus BHM) was coupled to a cooled 
intensified CCD video camera (GenIV ICCD, Princeton Instruments). Cremaster muscle 
capillaries were examined with a water immersion objective lens (Olympus; LUMPlanFL, NA 
0.9). The muscle was continuously (5 ml/min) superfused at 37°C with a bicarbonate-buffered 
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physiological salt solution (PSS). Texas Red labeled 40 kDa dextrans (Dex-40; Invitrogen) were 
intravenously injected at 10 mg/ml in PBS. Cremaster capillaries of 30-50m were chosen for 
examination from different microscopic field, and recorded on videotape using trans and epi-
illumination. After baseline recordings were made (15-20min) TNF-α (2ng/ml; Peprotech) was 
dropped on the Cremaster muscle for 5 minutes. Recordings of the same capillaries were made 
at baseline, after 60 and 120 minutes. 0.1 ml recombinant SPARC (15 microgram/kg, R and D 
systems) was injected i.v at a concentration of 0,15mg/kg prior to TNF-α stimulation. 0.1 ml 
(35U) of hyaluronidase was injected after the equilibration period and SPARC was injected 10 
minutes after the injection of hyaluronidase. Rolling leukocytes were measured by counting the 
visible passing leukocytes for 60 seconds. Counting cells that adhered to the vessel wall for ≥30 
seconds and did not move more than their own diameter in distance across the vessel wall 
during this period qualified as adherent leukocytes. Adhesion efficacy could be calculated by 
dividing the number of adherent leukocytes by the total number of rolling leukocytes. 
Leukocyte velocities were determined by measuring the time it took individual cells to travel 
150um in distance. Only cells that were visible during the entire course were include. Hokawo 
2.5 Wasabi Software and Image J 1.48v were used for post-hoc data analysis.   
 
Cardiac fractionation and flow cytometry  
Peripheral blood and the cardiac immune cell fractions were analysed using a  CantoII flow 
cytometer (Becton Dickenson (BD), San Diego, CA). Cells were first incubated with anti-
CD16/32 (eBioscience, San Diego, CA, #14-0161-85,1:100) to block Fc receptor binding. CD45+ 
leukocytes subpopulations were identified (Biolegend, #103129, 1:100)  and defined as follows: 
T lymphocytes (CD3+,eBioscience, # 57-0033-80,1:100), B lymphocytes (B220+,BD # 561226, 
1:50), Granulocytes (CD11b+, BD# 552850 1:2000, Ly6G+, BD# 560600, 1:100 ), Monocytes 
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(CD11b+, F4/80-, Biolegend #123116, 1:100, Ly6C+, Miltenyi # 130-093-134, 1:20). Absolute 
counts for cardiac and blood samples were determined with BD Truecount™ tubes according to 
the manufacturer’s instructions.  
 
Adhesion Assay 
Mouse endothelial cells (SVEC, simian virus 40-transformed mouse microvascular endothelial 
cells) were seeded on -slide VI0.4 (Ibidi, Planegg, Germany) and then stimulated with 10 ng/ml 
TNF- for 24 hours. 700 L of blood was isolate from either wild-type or knockout mice as 
indicated. The red blood cells were lysed to produce a mixed leukocyte population and stained 
with the intracellular fluorescent cell label carboxyfluorescein N-hydroxysuccinimidyl ester (or 
CFSE). Endothelial cells were then exposed to these leukocytes under flow.  To that end, the 
white blood cells from one mouse were added to at a concentration of 106/ mL. The flow rate 
was set to produce 1.25 dyne/cm2. Endothelial cells were exposed to white blood cells to flow 
for a period of 4 hours.  The system was flushed with PBS, and then the slides were transferred 
to a confocal microscope. Three images at random locations, chosen based on the transmitted 
light, were taken of the fluorescently labelled white blood cells.  The average number of 
adhered cells per unit area was calculated.   
Static adhesion assays where performed as follows: Spleens of SPARC WT and KO mice were 
removed and mashed over a 40μm mesh. Cell suspensions were then incubated with CD45+ 
beads (Miltenyi Biotech, Germany) according to the manufacturers instructions in order to 
isolate the monocytes. Isolated cells were labelled with CFSE (Molecular Probes, Invitrogen) 
and then placed on top of TNF-α (10ng/ml) stimulated mouse endothelial cells (SVEC, simian 
virus 40-transformed mouse microvascular endothelial cells) and allowed to adhere for 2 hours 
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at 37°C. Non-adherent cells were washed off and the remaining adhered cells quantified with a 
Victor 2 microplate reader (Perkin-Elmer, USA). 
 
Staining and Immunohistochemistry 
4 m thick sections were stained with CD45 (BD Pharmingen, catalog no. 553076, 1:100) for 
determining the amount of inflammation. Immunofluorescence of paraffin sections was 
performed according to protocol using antibodies against CD45 (BD Pharmingen, catalog no. 
553076, 1:100), CD31 (BD Pharmingen, catalog no. 557355, 1:500), VCAM-1 (BD Pharmingen, 
catalog no. 553330, 1:50) and SPARC (R&D, catalog no. AF942, 1:100). Images were acquired 
using Leica Qwin image processing software (Leica, Germany). 
 
Electron microscopy 
Hearts were fixed by perfusing 5-10ml of Glutaraldehyde 2,5%, Saccharose 12%, Na-cacodylate 
3 H2O 0,4M pH 7,3, lanthanum 4% pH 7,4 after which they were sectioned into small cubes that 
were fixed for another 2 hours. Samples were dehydrated in graded series of ethanol and 
embedded in Araldite (CY-212; Serva). Ultrathin sections were counterstained with uranium 
acetate and lead citrate prior to examination in a Philips CM100 electron microscope. 
 
Real time PCR  
Real-time reverse transcriptase–polymerase chain reaction (RT-PCR) analysis was performed 
(Bio-Rad, Maastricht, Netherlands) to determine transcript with the following primers; U6 
(FWD CGC-TTC-GGC-AGC-ACA-TAT-AC, BWD TTC-ACG-AAT-TTG-CGT-GTC-AT), MDA5 
(FWD GCC-TGG-AAC-GTA-GAC-GAC-AT, BWD TTG-GGC-CAC-TTC-CAT-TTG-GT), RIG-1 
(FWD AGA-CGG-TTC-ACC-GCA-TAC-AG, BWD AAG-CGT-CTC-CAA-GGA-CAG-TG), CVB3 
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(FWD ACG-AAT-CCC-AGT-GTG-TTT-TGG, BWD TGC-TCA-AAA-ACG-GTA-TGG-ACA-T), TLR3 
(FWD AGC-ATC-AAA-AGA-AGC-CGA-AA, BWD CTT-GCT-GAA-CTG-CGT-GAT-GT). Data were 
acquired and analyzed IQ5 software (Bio-Rad, Maastricht, Netherlands). 
 
Vascular Permeability Assay 
Vascular permeability experiments with Evans Blue dye were performed in heart, lung, liver, 
spleen and skin as previously described [68, 69]. Bead extravasation was done as follows; a 1:10 
dilution of red fluorescent microbeads (Invitrogen, Fluospheres) was tail vein injected. The 
beads were allowed to circulate for 2 minutes, before intracardiac perfusion of 1% PFA for 15 
minutes. Heart were then dissected, further fixed for 1 hour in 1% PFA, cryo-embedded, 
sectioned and then immunostained for VE-Cadherin (R&D Systems). Sections were imaged 
using z-sectioning on a confocal Zeiss LSM700. 
 
Echocardiographic and ECG recordings 
Animals were anesthetized and placed in a supine position on a heating pad to keep the internal 
body temperature between 37.5-37.7°C by using a rectal probe. Standard views were obtained 
in 2-D as well as M-mode by transthoracic echocardiography using a 12 MHz probe (Hewlett 
Packard, Amsterdam, the Netherlands) on a Visual Sonics echocardiograph. ECG signals were 
measured in SPARC KO and WT mice and QTc times were assessed for individual heartbeats. 
 
Statistical Analysis 
Results represent the mean ± SEM unless indicated otherwise. For murine studies, D´Agostino 
and Pearson’s omnibus normality test was performed. Statistical significance was determined 
by unpaired Student’s t test or ANOVA when data were normally distributed. Wilcoxon, Mann-
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Whitney or Kruskal-Wallis test was used for non-parametric data as indicated.  Gehan-Breslow-
Wilcoxon or Mantel-Cox test was used for survival analysis. Statistical analyses were performed 
with Prism GraphPad software v5.0. 
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Figure legends 
Figure 1: SPARC is needed to limit cardiac inflammation during viral myocarditis 
(A,B) CD45 staining and quantification of left ventricular sections 7 days after CVB3 injection 
showing increased cardiac leukocytes in SPARC KO hearts (*** p=0.0005 One-way ANOVA, 
n=11 and 10 for WT and KO respectively). (C) No difference was found in viral load between 
both genotypes. (D) Survival of SPARC KO and WT animals during CVB3 infection suggest 
increased mortality in SPARC KO mice (mortality: 7/12 in SPARC KO versus 4/14 in WT, p=0.06 
using Mantel-Cox method). (E,F) FACS analysis of circulating and cardiac leukocytes (CD45+ 
cells), granulocytes, monocytes and lymphocyte populations shows no differences between 
SPARC KO and WT mice in sham animals (E). However, while circulating leukocytes numbers 
remain unchanged four days after injection with CVB3 between genotypes, the amount of 
cardiac Ly6Chi monocytes and granulocytes were significantly increased in the SPARC KO mice 
as compared to WT mice (F, *p≤0.01, student’s T-test). Scale bar: 200 μm. 
 
Figure 2: SPARC is needed to maintain vascular barrier properties.  
 (A) SPARC showed positive staining in blood vessels coinciding Platelet endothelial cell 
adhesion molecule (PECAM-1) also known as cluster of differentiation 31 (CD31), vascular cell 
adhesion molecule-1 (VCAM-1) and with  Wheat Germ Agglutinin (WGA lectin specific for all 
sialic acid and N-acetylglucosamine that are present on glycoproteins within the extracellular 
space), but not with CD45+ leukocytes in the heart during viral myocarditis. All images shown 
are representative, scale bar: 50µm. (B) Labelled micro-beads were injected and visualized after 
counterstaining with vascular endothelial cadherin (VE-cadherin) revealing more extravasation 
in SPARC-KO animals. (Representative picture, red: micro-beads, green: VE-cadherin, 
scale=20μm, n= 3 per group) (C) Systemic injection of Evans Blue resulted in significantly more 
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uptake of Evans Blue in the myocardium of SPARC KO sham animals compared to WT sham 
animals (n=8, 6 for WT and KO respectively, *p<0.005, Student t-test). (D) Pull down of SPARC 
with protein A/G heparin coated sepharose beads in a cardiac endothelial cell lysate. The input 
in the first lane represents the total cell lysate. The second lane (depleted) shows the total cell 
lysate after incubation with the heparin coated sepharose beads. After an empty lane, the 
fourth lane then represents the pull down with the heparin sepharose beads. 
 
Figure 3: SPARC is needed for an intact endothelial glycocalyx hence impairs leukocyte 
recruitment. 
(A) Representative image illustrating the experimental setup of the Cremaster experiments, 
adjusted images provided by the university of Rochester. (B) Overview (right) and magnified 
(left) images of the microvasculature of the cremaster muscle illustrating Texas Red-labelled 
Dextran40 (40kDa) in the vasculature and its leakage in SPARC WT and KO mice untreated 
(control) and in response to TNF-α stimulation. (C) The microvascular leakage of texas red 
labelled Dextran40 was significantly higher in SPARC KO as compared to WT mice 
(****p=0.0001; Student t-test). Scale bar: 50μm. Measurements were performed in 25 and 26 
vessels from WT and KO mice respectively. (D) Electron microscopic imaging of cardiac 
capillaries and arterioles demonstrating compromised endothelial glycocalyx in heart sections 
of SPARC KO mice (scale bar: 500nm). (lu: Lumen, gly: glycocalyx, ec: endothelial cell). In vitro 
adhesive properties of leukocytes were no different under static or (E) flow conditions between 
WT and KO (n=3 per group for flow, n=5 per group for static). (G) Intra-vital microscopy of the 
cremaster muscle enabled the recording of leukocyte-endothelium interactions in SPARC WT 
and KO microvessels at baseline and after stimulation with TNFα. (H) Adhesion efficacy, 
calculated by dividing the number of adherent leukocytes by total rolling leukocytes, was 
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significantly higher in SPARC KO animals compared to WT. (I) Concordantly, cumulative 
frequency distribution of leukocyte velocities showed significant increased leukocyte velocities 
in WT animals both before and after TNFα stimulation (One-way ANOVA, KO vs WT *p<0.001; 
WT vs WT+TNFα #p<0.001; KO vs KO+TNFα ##p<0.001; WT+TNFα vs KO+TNFα  **p<0.001). 
Measurements were performed in more than 5 mice per group and 5 vessels per mouse, with 
≥15 leukocyte velocities quantified per vessel.  
 
Figure 4: Glycocalyx integrity is vital for limiting adverse inflammation  
(A) Electron microscopic imaging of microvessels showed clear glycocalyx degradation upon 
treatment with hyaluronidase (HAase). Recombinant SPARC treatment after glycocalyx 
degradation restored glycocalyx integrity. Scale bar: 200nm. (B-C) Representative images and 
quantification of vascular leakiness. After degradation of hyaluronan (one of the major 
components of the endothelial glycocalyx) with HAase the leakiness of texas red labelled 
Dextran40 (40kDa) increased, which could be restored by treatment with recombinant SPARC 
(***p<0.005; One-way ANOVA; scale bar: 50μm). Measurements were performed in 25, 23 and 
30 vessels from control, HAase and HAase+rSPARC treated animals respectively. (D) 
Significantly reduced leukocyte velocities were found in mice injected with HAase, which again 
could be reversed by administration of recombinant SPARC (Control vs HAase ***p=0.0001, 
HAase vs HAase+SPARC #p=0.01). (E) Representative images and quantification (F) of 
leukocyte (CD45+ cell) staining of left ventricular myocardial sections showing an increase in 
leukocyte infiltration in HAase treated mice compared to nontreated animals (*p<0.05, Student 
T-test; N=10, 8 for -HAase and +HAase treatment respectively). Scale bar: 200um. (G) Prior to 
myocardial immune cell infiltration we did not find a difference in viral presence in the 
myocardium of HAase treaded versus nontreated mice (n=4).  
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Figure 5: Recombinant SPARC administration reduces mortality and alleviates heart failure 
development. 
(A) Cardiac function significantly deteriorated in SPARC KO mice 9 weeks after viral exposure 
as compared to WT (*p<0.05). Administration of recombinant SPARC seemed to improve 
cardiac function in viral myocarditis. (B,C) Survival curve showing that administration of 
recombinant SPARC reduces the mortality in SPARC KO mice in response to viral exposure. 
(*p<0.01 using Mantel-Cox method, N=14, 12, 15 and 17 in WT, WT+rSPARC, KO and 
KO+rSPARC) (D,E) Recombinant SPARC administrated blunted the increased infiltration of 
immune cells in SPARC KO mice 7 days after CVB3 administration. (p<0.05; One-way ANOVA) 
(F,G) Lack of SPARC reduced the QTc time on electrocardiographic measurements significantly 
in KO mice compared to WT while not affecting the heart rate. (**p<0.01; One-way ANOVA). 
Fractional shortening and inflammation were measured in 11, 9, 9 and 14 WT, WT+rSPARC, KO 
and KO+rSPARC animals respectively. Scale bar: 50μm. 
 
Supplementary Figure 1 
 (A-C) No differences were found in the expression of virus recognition receptors Toll-Like-
Receptor 3 (TLR3), retinoic acid inducible gene-1 (RIG-1) and melanoma differentiation 
association protein-5 (MDA-5) upon viral exposure (n=5 per genotype). Student t-test 
performed. (D) There were no differences in troponin levels between SPARC WT and KO mice 7 
days after viral infection. 
 
Supplementary Figure 2 
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The uptake of Evans Blue was even more pronounced after viral infection in the heart, the lungs 
and the liver of SPARC KO animals (n=8, 5 for WT and KO respectively, *p<0.001, Student t-
test).  
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Table 1 
Time point Day 4 
 WT KO WT+S KO+S 
     
Survival 
 (%) 
14/14  
100% 
21/21  
100% 
12/12  
100% 
15/15 
100% 
LVIDd (mm) 3.7±0.5 3.7±0.3 3.6±0.2 3.5±0.2 
LVIDs (mm) 2.7±0.5 2.4±0.3 2.5±0.4 2.3±0.3 
FS (%) 27.5±6.4 34.9±4.9* 30.4±10.2 34.7±8.0 
HR (bpm) 
 
538±36 495±40 542±47 503±54 
LVIDd Left ventricular internal diameter end diastole; LVIDs Left ventricular  
internal diameter end systole; FS Fractional Shortening; HR Heart Rate 
+S refers to treatment with recombinant SPARC  
*WT vs KO p<0.05 
 
 
Time point Week 9 
 WT KO WT+S KO+S 
     
Survival 
(%) 
11/14 
78.6% 
9/21 
42.9% 
9/12 
75.0% 
14/15 
93.3% 
LVIDd (mm) 3.9±0.5 3.8±0.3 3.7±0.3 3.8±0.4 
LVIDs (mm) 2.7±0.6 2.8±0.5# 2.7±0.4 2.7±0.4 
FS (%) 30.3±9.5 25.8±7.1# 29.3±7.7 29.7±6.8 
HR (bpm) 
 
475±103 428±48 552±51.8 432±22.4 
# KO day 4 vs KO week 9 p<0.05 
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Highlights 
 The endothelial glycocalyx is an important extracellular matrix structure that 
regulates cardiac inflammation and mortality in viral myocarditis. 
 Absence of glycoprotein SPARC compromises the integrity of the endothelial 
glycocalyx. 
 Compromised endothelial glycocalyx integrity is demonstrated using intra-vital 
microscopy as well electron microscopy. 
 Restoring endothelial glycocalyx integrity by administration of SPARC reduces 
cardiac inflammation and mortality in viral myocarditis. 
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